(54) Title SPECIFIC BINDING PROTEINS AND USES THEREOF

(56) References

Cited: WO-A1-2009/023265, WO-A2-02/092771, PANOUSIS C ET AL: "Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.", BRITISH JOURNAL OF CANCER 28 MAR 2005 LNKD- PUBMED:15770208, vol.92, no.6, 28 March 2005 (2005-03-28) , pages 1069-1077, XP002578351, ISSN: 0007-0920, JOHNS T G ET AL: "Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY LNKD-DOI:10.1002/IJC.10189, vol.98, no.3, 20 March 2002 (2002-03-20) , pages 398-408, XP002343752, ISSN: 0020-7136, SCOTT ANDREW M ET AL: "A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 6 MAR 2007 LNKD- PUBMED:17360479, vol.104, no.10, 6 March 2007 (2007-03-06), pages 4071-4076, XP002578353, ISSN: 0027-8424, LIU XIAO-YUN ET AL: "Engineering therapeutic monoclonal antibodies.", IMMUNOLOGICAL REVIEWS APR 2008 LNKD- PUBMED:18363992, vol.222, April 2008 (2008-04), pages 9-27, XP002578352, ISSN: 1600-065X, DANAN LI ET AL: "Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant?dependent lung carcinomas", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol.117, no.2, 1 February 2007 (2007-02-01), pages 346-352, XP002576299, ISSN: 0021-9738, DOI:

10.1172/JCI30446 [retrieved on 2007-01-25], Chao: "Characterizing and engineering antibodies against the epidermal growth factor receptor", , February 2008 (2008-02), pages 53-54, 78, XP002578350, Retrieved from the Internet: URL:http://hdl.handle.net/1721.1/42076 [retrieved on 2010-04-15], PRESTA ET AL: "Engineering of therapeutic antibodies to minimize immunogenicity and optimize function", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL LNKD- DOI:10.1016/J.ADDR.2006.01.026, vol.58, no.5-6, 7 August 2006 (2006-08-07), pages 640-656, XP024892146, ISSN: 0169-409X [retrieved on 2006-08-07], PRESTA ET AL: "Molecular engineering and design of therapeutic antibodies", CURRENT

OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB LNKD-

DOI:10.1016/J.COI.2008.06.012, vol.20, no.4, 1 August 2008 (2008-08-01) , pages 460-470, XP023612046, ISSN: 0952-7915 [retrieved on 2008-08-06], JOHNS TERRANCE G ET AL: "Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 100, no.26, 23 December 2003 (2003-12-23), pages 15871-15876, XP002614292, ISSN: 0027-8424, DOI: 10.1073/PNAS.2036503100 [retrieved on 2003-12-15]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/